Bright Future for Rare Disease Patients Driven by Innovations Including Genomics and Personalized Medicine, But Some Challenges Remain

International Bio Convention

CSL Behring’s Bob Repella joined NORD’s Pam Gavin for a wide-ranging discussion about rare diseases at the 2016 BIO International Convention. The following is excerpted from his remarks.

By Bob Repella

Rare diseases are serious and often debilitating conditions that have a tremendous impact on 350 million patients worldwide, about half of whom are children, and their families. Today we are on the brink of significantly improving their lives through rare disease awareness, early diagnosis and innovative treatments.

More therapies are available today for previously unmet needs, and there are greater choices for patients than ever before. But even with this progress, a great deal of work remains to be done. Over 90% of the approximately 7,000 rare diseases have no treatment available, and there are still challenges to accessing existing therapies. Nevertheless, the trends overall are positive.

Continue reading


100 Years Old and Just Getting Started!

Centenary Logo

April 25, 2016
By Paul Perreault

Today we proudly mark CSL’s 100th anniversary, a milestone that is a testament to our values, science, people, and the patients we serve. For the past 100 years our vision, focus and agility have remained steadfast, enabling us to accomplish this feat. We have a rich heritage with an even brighter future. In many ways, we’re just getting started.

As a tangible expression of our values in action, and as a way of celebrating the CSL Centenary, we are establishing a $25 million R&D Fellowship program for early stage and translational research. The R&D Fellowship reflects the promise we made a century ago to save lives and protect people’s health.
Continue reading


Free Trade Helps Drive Innovation

March 19, 2015

By Anthony Farina

Paul Perreault, John-Berry, Niels Marquardt

Left to right: AMCHAM CEO Niels Marquardt, CSL Limited CEO and Managing Partner Paul Perreault, and U.S. Ambassador to Australia John Berry at Opportunity Australia 2015 in Philadelphia.

The U.S.-Australia Free Trade Agreement (FTA) has fostered substantial international trade in the ten years since it was forged between the two countries. The FTA is particularly significant for life sciences companies such as CSL Behring because it provides greatly expanded markets for products and patient care, and helps drive innovation.

The FTA is particularly significant for life sciences companies such as CSL Behring

Some of the policies covered in the FTA that sustain investments in innovation were highlighted today at Opportunity Australia 2015. The event was held in Philadelphia to mark the tenth anniversary of the agreement. John Berry, U.S. Ambassador to Australia participated in the event, which was hosted by the American Chamber of Commerce in Australia.
Continue reading

Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring.
This site is not intended as a forum for discussing CSL Behring or other companies' products.
Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.